Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade - Nouscom

Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade

By ef

Posted 09/27/2022

In Scientific publications

D’Alise AM et al., Nature Comms, 2019

Recent Posts

Nouscom Announces AACR 2023 Late-Breaking Presentation of Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy
NOUSCOM ANNOUNCES THE PROMOTIONS OF LOREDANA SIANI TO VICE PRESIDENT OF TECHNICAL AND CMC DEVELOPMENT, TIFFANY BROOKE MULLER TO SENIOR VICE PRESIDENT OF FINANCE AND MORENA D’ALISE TO VICE PRESIDENT OF IMMUNOLOGY
Nouscom announces appointment of Sarah Runswick as Senior Director of Clinical Science
Nouscom announces appointment of Yen-Ching Chua as Vice President of Clinical Operations

error: Content is protected !!!